Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of [14C]-DZD9008 in healthy male subjects
NCT05159895Phase 1Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Percentage of Total Radioactivity (Cum% Dose) Recovered in Urine Relative to the Administered Radioactive Dose up to 85 days, Percentage of Total Radioactivity (Cum% Dose) Recovered in Feces Relative to the Administered Radioactive Dose up to 85 days and 4 more. Started Sep 2021; status: completed.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05159895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159895.